Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Stopped This was a sponsor decision and was not a consequence of any safety concern

Conditions

• Triple Negative Breast Cancer (TNBC)

Interventions

• BIOLOGICAL: spartalizumab
• BIOLOGICAL: LAG525
• DRUG: NIR178
• DRUG: capmatinib
• BIOLOGICAL: MCS110
• BIOLOGICAL: canakinumab

Sponsor

Novartis Pharmaceuticals